A recent retrospective cohort study demonstrated that both TNF‐α inhibitors and non‐TNF‐α biologics (interleukin [IL]‐12/23, IL‐17, and IL‐23 inhibitors) are associated with a reduced risk of new‐onset and recurrent major adverse cardiovascular events (MACE) in patients with psoriasis [11]. Here, IL17A is linked to psoriasis.